A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences
UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending
GSK Commits $30 Billion to Bolster U.S. R&D and Manufacturing
GSK; $30 billion investment; U.S. expansion; R&D; manufacturing; biopharma; supply chain; advanced digital technologies
ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot
ArsenalBio; layoffs; biotech; staff reduction; restructuring; cell therapy; AB-2100; clinical trials; Bristol Myers Squibb partnership
Novo Nordisk and Bristol Myers Squibb Announce Major Layoffs in New Jersey
Novo Nordisk; Bristol Myers Squibb; layoffs; New Jersey; pharmaceutical industry; restructuring; job cuts; Ozempic; Wegovy; workforce reduction
Priovant Announces Successful Phase III Results for Brepocitinib in Dermatomyositis (VALOR Study)
Priovant; Roivant; brepocitinib; Phase III; VALOR study; dermatomyositis; clinical trial; Total Improvement Score; TIS; steroid reduction; cutaneous remission; NDA filing
AstraZeneca’s Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment
AstraZeneca; Saphnelo; anifrolumab; Phase III; TULIP-SC trial; systemic lupus erythematosus; SLE; self-injectable; subcutaneous; clinical trial; disease activity reduction
Aditum forms new company for China-sourced asset in $1B deal
Aditum; China-sourced asset; $1B deal; newco; Mabwell; dyslipidemia; vascular disorders; biotech licensing; cross-border pharma
X4 Pharma Halves Workforce in Second Round of 2025 Layoffs
X4 Pharmaceuticals; layoffs; restructuring; chronic neutropenia; mavorixafor; management changes; biotech
Regeneron Prepares U.S. Submission for Garetosmab After Breakthrough Phase III Result in Ultra-Rare FOP
Regeneron; garetosmab; FOP; fibrodysplasia ossificans progressiva; Phase III; OPTIMA trial; bone lesion prevention; rare disease; FDA submission; orphan drug
FDA Scrutinizes Telehealth Firms Like Hims for GLP-1 Drug Advertising Practices
FDA; Hims; telehealth; GLP-1; advertising; weight-loss drugs; compound drugs; Super Bowl ad; misleading claims